IP Library Granted Patent US 7,189,761
Granted Patent B2
US 7,189,761 · App. 10/669,099 · Granted Mar 13, 2007

Nitric oxide donor composition and method for treatment of anal disorders

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,189,761
App. No.
10/669,099
Granted
Mar 13, 2007
Kind
B2
Abstract

A pharmaceutical composition contains a nitric oxide donor and advantageously an optional corticosteroid and/or topical anesthetic. The composition is useful in a method for treating anal disorders such as anal fissure, anal ulcer, hemorrhoidal disease, levator spasm, and so forth, by topical application to or proximate the affected area.

Claims (26)

1. A method for ameliorating pain in a human patient associated with an anal disorder selected from one or more of the group consisting of anal fissure, anal ulcer, and hemorrhoidal disease, comprising administering an effective amount of an organic nitric oxide donor proximate to, or to, the affected area of the patient, and wherein said method the pain is ameliorated.

2. The method of claim 1 , wherein said anal disorder is an anal fissure or ulcer.

3. The method of claim 1 , wherein said anal disorder is hemorrhoidal disease.

4. The method of claim 1 , wherein the organic nitric oxide donor is capable of releasing nitric oxide under physiological conditions.

5. The method of claim 4 , wherein the administering is topical and the nitric oxide donor is formulated as an ointment, a cream, a gel, or a lotion.

6. The method of claim 5 , wherein the organic nitric oxide donor is applied to a hemorrhoid.

7. The method of claim 5 , wherein the organic nitric oxide donor is applied to an anal fissure or anal ulcer.

8. The method of claim 4 , wherein the administering is topical and the nitric oxide donor is formulated as a liquid or semisolid.

9. The method of claim 4 , wherein the nitric oxide donor is formulated as a suppository.

10. The method of claim 4 , wherein the organic nitric oxide donor is formulated in a composition comprising the nitric oxide donor in an amount from 0.0 1% to 10% by weight and a physiologically acceptable carrier.

11. The method of claim 1 , wherein the organic nitric oxide donor is capable of releasing nitric oxide under anal disease treatment conditions.

12. The method of claim 1 , wherein the administering is topical.

13. The method of claim 1 , wherein the administering is via a suppository.

14. The method of claim 1 , wherein the organic nitric oxide donor is applied proximate to the affected area of the patient.

15. The method of claim 1 , wherein the organic nitric oxide donor is applied to the affected area of the patient.

16. The method of claim 1 , wherein the organic nitric oxide donor is formulated in a composition comprising the nitric oxide donor in an amount from 0.01% to 10% by weight and a physiologically acceptable carrier.

17. The method of claim 16 , wherein the composition further comprises a carrier selected from the group consisting of white petrolatum, mineral oil, lanolin, distilled water, acetone, and cocoa butter.

18. The method of claim 16 , wherein the composition further comprises a corticosteroid.

19. The method of claim 16 , wherein the composition further comprises a local anesthetic.

20. The method of claim 16 , wherein the composition is formulated as an ointment, a cream, a gel, or a lotion.

21. The method of claim 16 , wherein the composition is formulated as a liquid or semisolid.

22. The method of claim 16 , wherein the composition is formulated as a suppository.

23. A method of treating a human patient having pain associated with an anal fissure, anal ulcer, or hemorrhoid, comprising applying a composition comprising an effective amount of an organic compound which can release nitric oxide under physiological or anal disease treatment conditions and a physiologically acceptable carrier to an area proximate to, or to, the affected area-of the patient, wherein said method the pain is ameliorated.

24. A method of claim 23 , wherein the affected area has a hemorrhoid.

25. A method of claim 23 , wherein the affected area has an anal ulcer or anal fissure.

26. A method of claim 23 , wherein the organic compound is formulated as a suppository.

Assignments (8)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 17, 2011
From: NEPTUNE PHARMACEUTICAL CORPORATION
To: CELLEGY PHARMACEUTICALS, INC.
Reel/Frame 027247/0012 →
CHANGE OF NAME Recorded Nov 17, 2011
From: STRAKAN INTERNATIONAL LIMITED
To: STRAKAN INTERNATIONAL S.A.R.L.
Reel/Frame 027247/0647 →
RELEASE OF PATENT SECURITY AGREEMENT Recorded Nov 10, 2011
From: MORGAN STANLEY BANK INTERNATIONAL LIMITED, AS SECURITY TRUSTEE
To: STRAKAN INTERNATIONAL LIMITED
Reel/Frame 027212/0299 →
PATENT SECURITY AGREEMENT Recorded Mar 30, 2007
From: STRAKAN INTERNATIONAL LIMITED
To: MORGAN STANLEY BANK INTERNATIONAL LIMITED
Reel/Frame 019094/0323 →
TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENTS Recorded Mar 21, 2007
From: STRAKAN INTERNATIONAL LIMITED
To: CELLEGY PHARMACEUTICALS, INC.
Reel/Frame 019035/0964 →
MERGER Recorded Feb 28, 2007
From: CELLEGY PHARMACEUTICALS, INC.
To: CELLEGY PHARMACEUTICALS, INC.
Reel/Frame 018942/0268 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 27, 2007
From: CELLEGY PHARMACEUTICALS, INC.
To: STRAKAN INTERNATIONAL LIMITED
Reel/Frame 018934/0497 →
SECURITY INTEREST Recorded Sep 29, 2006
From: CELLEGY PHARMACEUTICALS, INC.
To: STRAKAN INTERNATIONAL LIMITED
Reel/Frame 018338/0001 →